- Home
- BBIO vs HRL Comparison
BBIO vs HRL Comparison
Compare BBIO & HRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | HRL |
|---|---|---|
| Founded | 2015 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 12.9B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BBIO | HRL |
|---|---|---|
| Price | $74.32 | $22.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 6 |
| Target Price | ★ $78.43 | $28.00 |
| AVG Volume (30 Days) | 1.9M | ★ 4.5M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 5.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.87 |
| Revenue | $353,780,000.00 | ★ $12,106,160,000.00 |
| Revenue This Year | $127.64 | $3.42 |
| Revenue Next Year | $78.38 | $2.24 |
| P/E Ratio | ★ N/A | $25.70 |
| Revenue Growth | ★ 62.46 | 1.55 |
| 52 Week Low | $28.10 | $21.03 |
| 52 Week High | $78.59 | $32.07 |
Technical Indicators
Market Signals| Indicator | BBIO | HRL |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 39.54 |
| Support Level | $71.19 | $22.82 |
| Resistance Level | $75.57 | $24.46 |
| Average True Range (ATR) | 2.44 | 0.42 |
| MACD | -0.65 | -0.20 |
| Stochastic Oscillator | 38.54 | 23.15 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.